Follow the Money to Medical Device & Diagnostic Opportunities
Spotlight on Organogenesis, Inc.

by

Follow the Money to Medical Device & Diagnostic Opportunities highlights a newly funded medical device or diagnostic company. This includes important insights into the featured company’s product pipeline, manufacturing and business relationships, and likely sourcing opportunities.

Organogenesis is a private US company that focuses on regenerative medicine, specializing in bio-active wound healing, oral regeneration and bio-surgery. It raised $30 million in a completion of a venture capital investment, as reported in the PharmSource Lead Sheet on April 21, 2016.

Corporate Highlights

  • Organogenesis was founded in 1985 as a spin-off of technology developed at the Massachusetts Institute of Technology (MIT)
  • Corporate Headquarters: Canton, MA
  • International Headquarters: Reinach, Switzerland
  • The company has over 600 employees in the US

Sourcing Opportunities

  • Organogenesis plans to use the proceeds for new product development and to support the expansion of commercial operations and its sales force.
  • Organogenesis owns and operates manufacturing facilities in Canton, MA and La Jolla, CA.

Business Relationships

  • In August 2014, Organogenesis and the Department of Veteran Affairs entered into a 5-year supply agreement for Apligraf for the treatment of diabetic foot ulcers and venous leg ulcers. The contract included an option to extend the duration of the supply agreement for an additional five years. Financial terms were undisclosed.
  • In January 2014, Organogenesis acquired all assets to Shire’s living skin substitute Dermagraft for the treatment of diabetic foot ulcers. Organogenesis paid Shire $683 million, including up to $300 million in milestone payments until 2018.

Previous Financings

  • December 2010: $457,899 in a completed government grant

Medical Device & Diagnostics Pipeline

Product Candidate Indication Medical Specialty Purpose Type
Apligraf Diabetic foot ulcers/
Venous leg ulcers
Dermatology/Wound Care
Cell & Tissue Processing
Device-Therapeutic/
Interventional
Other
Dermagraft Diabetic foot ulcers Dermatology/Wound Care
Diabetes/Endocrinology
Surgery
Device-Therapeutic/
Interventional
Dressing/Material/
Liner/Mesh
PuraPly Acute and chronic wound care Dermatology/Wound Care Device-Therapeutic/
Interventional
Dressing/Material/
Liner/Mesh

Regulatory Approvals and Clearances1

Product Candidate Region Approval/Clearance Year of Approval or Clearance
Apligraf Switzerland Regulatory approval 2015
Dermagraft Canada Health Canada approval 2012
PuraPly United States United States 2001
Dermagraft United States PMA approval 2001
Apligraf United States PMA approval 2000

1Source: PharmSource Lead Sheet

Contact Information

Organogenesis, Inc. Key Officers
85 Dan Road Gary S. Gillheeney, President & CEO
Canton, MA 02021-2820 USA Phillip Nolan, VP, Manufacturing Operations
Phone: +1-781-575-0775 Vincent Ronfard, PhD, VP, R&D
Fax: +1-781-575-1570 Zorina Pitkin, PhD, VP, Quality Systems
Web: www.organogenesis.com Patrick Bilbo, VP, Regulatory

Related posts:
Follow the Money: ArQule, Inc.
Follow the Money: Amarantus Bioscience Holdings, Inc.
Follow the Money: Acceleron Pharma, Inc.

Scotty is a Research Analyst at PharmSource. He holds a BS degree in Biology from George Mason University and an MPH degree from Eastern Virginia Medical School. He’s experienced in data collection, analysis and management, and has done laboratory analysis and safety program development.

More posts by Scotty Chung-Siu